XmAb5871, a humanized monoclonal antibody using selective dual-targeting mechanism for B cell inhibition by targeting the antigen CD19 and co-engaging CD32b (Fc?RIIb), helps in suppression of autoimmune response.
Preclinical studies demonstrated that XmAb5871 suppresses autoimmune response in humanized mouse models of systemic lupus erythematosus (SLE), without the depletion of B cells.
The endpoints of the Phase 1 study are safety, pharmacokinetics and a number of biomarkers of immunomodulatory drug activity.